Serratia marcescens
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | 4 |
0 | 0 | 0 | 0 |
Azithromycin | - |
- | - |
- | - |
Aztreonam | 94 |
97 | 96 |
96 | 93 |
Cefazolin | 0 |
0 | 0
0 |
0 |
|
Cefepime | 96 |
100 | 100
100 |
100 |
|
Ceftazidime | 92 |
89 | 97 |
96 | 91 |
Ceftriaxone | 97 |
99 | 93 |
94 | 89 |
Cefuroxime | 0 |
0 | 0
0 |
0 |
|
Ciprofloxacin | 93 |
91 | 96 |
95 | 94 |
Clarithromycin | - |
- | - |
- | - |
Clindamycin | - |
- | - |
- | - |
Doxycycline | 16 |
14 | 15 |
- | - |
Erythromycin | - |
- | - |
- | - |
Gentamicin | 99 |
99 | 99 |
99 | 99 |
Imipenem | 99 |
99 | 97 |
99 | 99 |
Levofloxacin | 95 | 96 | 99 | 98 | 94 |
Meropenem | + | 99 | 99 | 100 | 100 |
Moxifloxacin | + | + | + | + | + |
Nitrofurantoin | 0 | 0 | 0 | 0 | 0 |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | - | - | - | - | - |
Piperacillin | 83 | 93 | 77 | + | + |
Piperacillin/tazo | 93 | 92 | 93 | 96 | 91 |
Ticarcillin/Clav | + | + | + | + | + |
Tobramycin | 93 | 89 | 93 | 97 | 93 |
TMP/SMX | 94 | 99 | 99 | 97 | 99 |
Unasyn/Aug | 3 | 0 | 0 | 0 | 0 |
Vancomycin | - | - | - | - | - |
# Tested | 89 | 78 | 94 | 123 | 89 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections